Cadila Healthcare on Friday reported a 53.3% jump in consolidated net profit at ₹590.8 crore for the fourth quarter ended March 31, 2018.
The company had posted a consolidated net profit of ₹385.5 crore in the same quarter a year earlier, Cadila Healthcare said in a BSE filing.
Separately, Zydus Cadila said it had received final approval from USFDA to market Dutasteride and Tamsulosin Hydrochloride capsules. The drug is used to treat symptoms of Benign Prostatic Hyperplasia (BPH) — also called prostate gland enlargement.
